FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4226200819> ?p ?o ?g. }

• W4226200819 endingPage "1717" @default.
• W4226200819 startingPage "1707" @default.
• W4226200819 abstract "OBJECTIVE Clazosentan has been investigated globally for the prevention of cerebral vasospasm after aneurysmal subarachnoid hemorrhage (aSAH). The authors evaluated its effects on vasospasm-related morbidity and all-cause mortality following aSAH in Japanese patients. METHODS Two similar double-blind, placebo-controlled phase 3 studies were conducted in 57 Japanese centers in patients with aSAH, after aneurysms were secured by endovascular coiling in one study and surgical clipping in the other. In each study, patients were randomly administered intravenous clazosentan (10 mg/hr) or placebo (1:1) starting within 48 hours of aSAH and for up to 15 days after aSAH. Stratified randomization based on World Federation of Neurosurgical Societies grade was performed using a centralized interactive web response system. Vasospasm-related morbidity and all-cause mortality within 6 weeks post-aSAH, including new cerebral infarcts and delayed ischemic neurological deficits as well as all-cause mortality, were the first primary endpoint in each study. The second primary endpoint was all-cause morbidity (new cerebral infarct or delayed ischemic neurological deficit from any causes) and all-cause mortality (all-cause morbidity/mortality) within 6 weeks post-aSAH. The incidence of individual components of the primary morbidity/mortality endpoints within 6 weeks and patient outcome at 12 weeks post-aSAH (including the modified Rankin Scale scores) were also evaluated. The above analyses were also performed in the population pooled from both studies. RESULTS In each study, 221 patients were randomized and 220 were included in the full analysis set of the primary analysis (109 in each clazosentan group, 111 in each placebo group). Clazosentan significantly reduced the incidence of vasospasm-related morbidity and all-cause mortality after aneurysm coiling (from 28.8% to 13.6%; relative risk reduction 53%; 95% CI 17%–73%) and after clipping (from 39.6% to 16.2%; relative risk reduction 59%; 95% CI 33%–75%). All-cause morbidity/mortality and poor outcome (dichotomized modified Rankin Scale scores) were significantly reduced by clazosentan after preplanned study pooling. Treatment-emergent adverse events were similar to those reported previously. CONCLUSIONS Clazosentan significantly reduced the combined incidence of vasospasm-related morbidity and all-cause mortality post-aSAH with no unexpected safety findings. Clinical trial registration nos.: JapicCTI-163368 and JapicCTI-163369 ( https://www.clinicaltrials.jp )" @default.
• W4226200819 created "2022-05-05" @default.
• W4226200819 creator A5010733704 @default.
• W4226200819 creator A5036599054 @default.
• W4226200819 creator A5064749082 @default.
• W4226200819 creator A5074615107 @default.
• W4226200819 creator A5086795177 @default.
• W4226200819 creator A5090356821 @default.
• W4226200819 creator A5091370319 @default.
• W4226200819 date "2022-12-01" @default.
• W4226200819 modified "2023-10-15" @default.
• W4226200819 title "Effects of clazosentan on cerebral vasospasm–related morbidity and all-cause mortality after aneurysmal subarachnoid hemorrhage: two randomized phase 3 trials in Japanese patients" @default.
• W4226200819 cites W1969965845 @default.
• W4226200819 cites W2007345509 @default.
• W4226200819 cites W2027913805 @default.
• W4226200819 cites W2033557350 @default.
• W4226200819 cites W2059947861 @default.
• W4226200819 cites W2060752639 @default.
• W4226200819 cites W2073420814 @default.
• W4226200819 cites W2078919465 @default.
• W4226200819 cites W2082657386 @default.
• W4226200819 cites W2100404452 @default.
• W4226200819 cites W2102182787 @default.
• W4226200819 cites W2111062482 @default.
• W4226200819 cites W2121507314 @default.
• W4226200819 cites W2149723174 @default.
• W4226200819 cites W2150982420 @default.
• W4226200819 cites W2151499339 @default.
• W4226200819 cites W2154601847 @default.
• W4226200819 cites W2157540829 @default.
• W4226200819 cites W2162804111 @default.
• W4226200819 cites W2421796923 @default.
• W4226200819 cites W2589391887 @default.
• W4226200819 cites W2610536880 @default.
• W4226200819 cites W2908561956 @default.
• W4226200819 cites W2909576376 @default.
• W4226200819 cites W2921173529 @default.
• W4226200819 cites W2977606917 @default.
• W4226200819 cites W3027860996 @default.
• W4226200819 doi "https://doi.org/10.3171/2022.2.jns212914" @default.
• W4226200819 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35364589" @default.
• W4226200819 hasPublicationYear "2022" @default.
• W4226200819 type Work @default.
• W4226200819 citedByCount "13" @default.
• W4226200819 countsByYear W42262008192022 @default.
• W4226200819 countsByYear W42262008192023 @default.
• W4226200819 crossrefType "journal-article" @default.
• W4226200819 hasAuthorship W4226200819A5010733704 @default.
• W4226200819 hasAuthorship W4226200819A5036599054 @default.
• W4226200819 hasAuthorship W4226200819A5064749082 @default.
• W4226200819 hasAuthorship W4226200819A5074615107 @default.
• W4226200819 hasAuthorship W4226200819A5086795177 @default.
• W4226200819 hasAuthorship W4226200819A5090356821 @default.
• W4226200819 hasAuthorship W4226200819A5091370319 @default.
• W4226200819 hasBestOaLocation W42262008191 @default.
• W4226200819 hasConcept C126322002 @default.
• W4226200819 hasConcept C127413603 @default.
• W4226200819 hasConcept C141071460 @default.
• W4226200819 hasConcept C142724271 @default.
• W4226200819 hasConcept C168563851 @default.
• W4226200819 hasConcept C203092338 @default.
• W4226200819 hasConcept C204787440 @default.
• W4226200819 hasConcept C27081682 @default.
• W4226200819 hasConcept C2776098176 @default.
• W4226200819 hasConcept C2776820941 @default.
• W4226200819 hasConcept C2777294900 @default.
• W4226200819 hasConcept C2777736543 @default.
• W4226200819 hasConcept C2778506911 @default.
• W4226200819 hasConcept C2779905414 @default.
• W4226200819 hasConcept C2780645631 @default.
• W4226200819 hasConcept C2780931571 @default.
• W4226200819 hasConcept C2908647359 @default.
• W4226200819 hasConcept C3018386432 @default.
• W4226200819 hasConcept C3020199598 @default.
• W4226200819 hasConcept C42219234 @default.
• W4226200819 hasConcept C519063684 @default.
• W4226200819 hasConcept C541997718 @default.
• W4226200819 hasConcept C71924100 @default.
• W4226200819 hasConcept C78519656 @default.
• W4226200819 hasConcept C99454951 @default.
• W4226200819 hasConceptScore W4226200819C126322002 @default.
• W4226200819 hasConceptScore W4226200819C127413603 @default.
• W4226200819 hasConceptScore W4226200819C141071460 @default.
• W4226200819 hasConceptScore W4226200819C142724271 @default.
• W4226200819 hasConceptScore W4226200819C168563851 @default.
• W4226200819 hasConceptScore W4226200819C203092338 @default.
• W4226200819 hasConceptScore W4226200819C204787440 @default.
• W4226200819 hasConceptScore W4226200819C27081682 @default.
• W4226200819 hasConceptScore W4226200819C2776098176 @default.
• W4226200819 hasConceptScore W4226200819C2776820941 @default.
• W4226200819 hasConceptScore W4226200819C2777294900 @default.
• W4226200819 hasConceptScore W4226200819C2777736543 @default.
• W4226200819 hasConceptScore W4226200819C2778506911 @default.
• W4226200819 hasConceptScore W4226200819C2779905414 @default.
• W4226200819 hasConceptScore W4226200819C2780645631 @default.
• W4226200819 hasConceptScore W4226200819C2780931571 @default.
• W4226200819 hasConceptScore W4226200819C2908647359 @default.
• W4226200819 hasConceptScore W4226200819C3018386432 @default.

• next